SCHEMBL5537527

SCHEMBL5537527

[c]1cccc(C/C=C/c2ccccc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.43
IDO1 P14902 2/20 0.39
PAM P19021 1/20 0.39
PTGER4 P35408 1/20 0.37
PTGER3 P43115 1/20 0.37
PTGER2 P43116 1/20 0.37
HTR2A P28223 3/20 0.37
ALDH1A1 P00352 3/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
ARG2 P78540 1/20 0.35
LTA4H P09960 1/20 0.35
KDM4E B2RXH2 2/20 0.35
MAPT P10636 2/20 0.35
MEN1 O00255 1/20 0.35
RECQL P46063 1/20 0.35
KMT2A Q03164 1/20 0.35
PPARG P37231 1/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537530 1.00 MAOB (0.43) MAOBIDO1PAMPTGER4PTGER3
SCHEMBL163963 0.80 MAOB (0.67) MAOBIDO1PAMPTGER4PTGER3
SCHEMBL1892917 0.80 MAOB (0.67) MAOBIDO1PAMPTGER4PTGER3
SCHEMBL4256257 0.80 MAOB (0.67) MAOBIDO1PAMPTGER4PTGER3
SCHEMBL15456006 0.79 MAOB (0.54) MAOBIDO1PAMPTGER4PTGER3
SCHEMBL5544504 0.79 MAOB (0.48) MAOBIDO1PAMPTGER4PTGER3
SCHEMBL5544508 0.79 MAOB (0.48) MAOBIDO1PAMPTGER4PTGER3
Fluoride SCHEMBL28109078 0.78 MAOB (0.64) MAOBIDO1PAMPTGER4PTGER3
SCHEMBL3821231 0.76 MAOB (0.38) MAOBCA1CA2ARG2TP53
SCHEMBL9454376 0.76 MAOB (0.38) MAOBCA1CA2ARG2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAOB 2140/4885IDO1 3181/4885PAM 1855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.